A practical reference on Cardarine: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
== Morphine ester chemistry == Another name for this drug is 3-acetyl-6-propionylmorphine, and it is produced by the acetylation of 6-propionylmorphine, an active opioid which is an ester of morphine first produced along with heroin and numerous other mono-, di-, and tetra- esters of morphine in the United Kingdom in 1872–1876 and then shelved; 6-propionylmorphine was later researched by firms and organizations in Italy, Austria, Germany, the United States, the United Kingdom and elsewhere. Functional groups which are added to morphine and its esters to make active opioids include the benzoyl, acetyl, formyl, propionyl, butroyl, butyl, salicoyl, nicotinoyl, cinnamoyl, and others. It was discovered shortly after the development of dihydromorphine (discovered in nature or first synthesised circa 1880, commercially available in 1900), hydromorphone (first synthesised 1924), and oxymorphone (synthesised 1914), that mono, di, tri, and perhaps tetra- esters could be developed from them as well. A smaller number of esters of codeine, hydrocodone, and dihydrocodeine, and one or two of oxycodone are also known and used in medicine.
== Appearances == According to the backstory presented during Half-Life 2, the Combine appear on Earth after the death of the Nihilanth (the boss character at the end of Half-Life, who was killed by Gordon Freeman in an attempt to stop the "resonance cascade"). The death of the Nihilanth, a powerful creature controlling the dimensional rip between Xen and the Black Mesa Research Facility on Earth, causes the rip to worsen, resulting in "portal storms" which spread the hostile wildlife of Xen across Earth. The Combine manipulate this tear in the spacetime continuum, widening it to allow access to Earth from their dimension. When sufficiently wide enough, the Combine launched an invasion in force. Earth is rapidly defeated in a war lasting seven hours (the title is a reference to the Soviet military exercise Щит-82; "Seven-Hour Nuclear War"). Earth's surrender was negotiated by Dr. Wallace Breen, administrator of the Black Mesa Research Facility at the time of the incident, who discovered a means of communicating with the Combine. Dr. Breen was subsequently made the Combine's puppet ruler of Earth, with City 17 as his base of operations. Following their conquering of Earth the Combine installed a totalitarian state, introduced a reproductive suppression field intended to stop human reproduction, and exploited the Earth's population as well as its natural and human-made resources for its own benefit. The Combine's first appearance is in Half-Life 2.
When herbivores are moved around leaves of wild type plants, they reach similar masses to herbivores that consume only mutant plants, implying the effects of JAs are localized to sites of herbivory. Studies have shown that there is significant crosstalk between defense pathways.
The Japanese attack on Pearl Harbor in December 1941 led to a change in Roosevelt's position. He transformed his trusteeship proposal into a proposal for Four Policemen – the United States, the United Kingdom, the Soviet Union, and China – to enforce the peace after the war for several years while other nations, friend and foe, would be disarmed. Roosevelt made his first references to the Four Policemen proposal in early 1942. This would not preclude the eventual formation of a worldwide organisation of nations "for the purpose of full discussion" provided "management" was left to the Four Policemen. He presented his postwar plans to Soviet foreign minister Vyacheslav Molotov, who had arrived in Washington on May 29 to discuss the possibility of launching a second front in Europe. The President said to Molotov that "he could not visualize another League of Nations with 100 different signatories; there were simply too many nations to satisfy, hence it was a failure and would be a failure". Roosevelt told Molotov that the Big Four must unite after the war to police the world and disarm aggressor states. When Molotov asked about the role of other countries, Roosevelt answered by opining that too many "policemen" could lead to infighting, but he was open to the idea of allowing other allied countries to participate. A memorandum of the conference summarizes their conversation:
Sources: en.wikipedia.org
The War of the Fifth Coalition ended with the Treaty of Schönbrunn (14 October 1809). In the east, only the Tyrolese rebels led by Andreas Hofer continued to fight the French-Bavarian army until finally defeated in November 1809. In the west, the Peninsular War continued. Economic warfare between Britain and France continued: The British continued a naval blockade of French-controlled territory. Due to military shortages and lack of organisation in French territory, many breaches of the Continental System occurred and the French Continental System was largely ineffective and did little economic damage to Great Britain. Both sides entered further conflicts in attempts to enforce their blockade. As Napoleon realised that extensive trade was going through Spain and Russia, he invaded those two countries; the British fought the United States in the War of 1812 (1812–1815). In 1810, the French Empire reached its greatest extent. Napoleon married Marie-Louise, an Austrian Archduchess, with the aim of ensuring a more stable alliance with Austria and of providing the Emperor with an heir (something his first wife, Joséphine, had failed to do). As well as the French Empire, Napoleon controlled the Swiss Confederation, the Confederation of the Rhine, the Duchy of Warsaw and the Kingdom of Italy. Territories allied with the French included:
== P == Palladin Plastin p30 PAK (p21-activated Kinase) Plectin p47PHOX Parvin (actopaxin) Prefoldin p53 PASK (Proline, Alanine rich Ste20 related Kinase) Presenilin I p58 Phalloidin (not a protein; a small cyclic peptide) Profilin p185neu Ponticulin Protein kinase C Porin P.IB Prk1p (actin regulating kinase)
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs. It acts against interleukin 31 (IL-31), which is a cytokine involved in causing itchiness (pruritus). Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks. The United States Department of Agriculture (USDA) approved lokivetmab (manufactured by Zoetis and sold under the trade name Cytopoint) in December 2016, and it was approved by the European Medicines Agency in 2017. Lokivetmab was the first monoclonal antibody to be approved for use in animals in the European Union.
Sources: en.wikipedia.org
=== Ansa-bridging macrolactone === The ansa-bridging macrolactone was constructed following the first Sonogashira coupling, using the Shiina macrolactonization. This protocol was performed on the gram-scale without diminishing its yield employing 2-methyl-6-nitrobenzoic anhydride, 4-dimethylaminopyridine, and triethylamine as a base to promote intramolecular esterification.
Endotoxins are the lipid portions of lipopolysaccharides that are part of the outer membrane of the cell wall of gram-negative bacteria. Endotoxins are released when the bacteria lyses, which is why after antibiotic treatment, symptoms can worsen at first as the bacteria are killed and they release their endotoxins. Exotoxins are secreted into the surrounding medium or released when the bacteria die and the cell wall breaks apart.
Bush then issued a statement saying that while Trump was within his rights to call for recounts, he believed the election was "fundamentally fair" and that "its outcome is clear", and said he would offer Biden "my prayers for his success, and my pledge to help in any way I can", as he had for Trump and Obama.
Aromas can be formed via amino acid decomposition, Maillard reaction, sugar cyclization, and lipid oxidation. A complex mix of aromas similar to butter, meat, bone stock, wood smoke, lovage and many other substances can be produced, depending on reaction conditions (time, temperature, hydrolysis method, additional feedstock such as xylose and spices). According to the European Code of Practice for Bouillons and Consommés, hydrolyzed protein products intended for retail sale correspond to these characteristics:
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.